We harness the power of machine learning to move beyond experimental screening found in traditional therapeutic antibody discovery and engineering processes. To achieve this, we combine three state-of-the-art techniques in protein engineering: gene editing, deep sequencing, and deep learning. With our proprietary mammalian system and drug discovery workflow, we generate thousands of optimized lead candidates ready for preclinical studies at a fraction of the time and cost.
13.12.2021
deepCDR Biologics gets acquired by Alloy Therapeutics to advance bioinformatics and machine learning (venturelab.swiss)
09.12.2021
Alloy Therapeutics acquires deepCDR Biologics (startupticker.ch)
17.11.2021
The Venture Leaders Biotech dive into the Boston ecosystem (venturelab.swiss)
11.10.2021
Meet deepCDR co-founder Simon Friedensohn and find out how he advances the therapeutic antibody discovery process (venturelab.swiss)
30.09.2021
Sino-Swiss Pitchinar: Selected Swiss biotech startups pitch to Chinese investors and enterprises (venturelab.swiss)
No milestones
No Jobs
No videos and documents
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
The IMD Startup Competition provides an unique opportunity for regional technology startups to benefit from the help and insights of a team of dedicated, experienced IMD participants from the MBA and the Executive MBA programs.
Website:
www.deepcdr.com
Headquarter:
Basel
Foundation Date:
March 2019
Technology:
Sectors: